same concentration. They also described morphologically that vacuoles were smaller when infected cells were treated with lovastatin compared with untreated cells. However, they did not use a quantitative method to prove this effect. Our method, in which we coupled imaging and software analysis, allows quantitative determination of differences in vacuole size and number.
Interestingly, pravastatin did not have any apparent effect in reducing C. burnetii infection. Pravastatin is hydrophilic and seems to be less effective than other statins in different models. 4 This could be due to different pharmacokinetic properties compared with other statins 4 and may explain the lack of activity of pravastatin in our C. burnetii model of infection. In our study, lovastatin was effective at a concentration achievable in the sera of patients treated with this drug. This drug does not seem to interfere with bacterial entry in cells, as internalization by cells was not different from controls, as also reported for Salmonella Typhimurium. 5 We hypothesize that lovastatin indirectly reduces C. burnetii growth by modifying cholesterol-rich vacuoles. However, a minimal direct effect on bacteria could not eventually be eliminated, as the genome of C. burnetii contains some genes involved in the steroid biosynthesis pathway, especially that encoding the HMG CoA reductase, available at the KEGG web site (http://www.genome.jp/dbget-bin/get_pathway?org_name= cbu&mapno=00100). In vitro studies with statins in association with doxycycline could be performed in the future to look for a possible synergistic inhibitory effect on C. burnetii. Because the inhibitory effect of statins was seen only with pre-incubated cells, we believe that lovastatin may be effective in prophylaxis. These findings need to be confirmed using an animal model 6 and/or epidemiological case-control study, especially in patients with chronic Q fever.
Sir, We reported the in vitro activity of tigecycline against 148 strains of Acinetobacter spp. from the infectious diseases research laboratory at Siriraj Hospital, Bangkok, Thailand, which showed that only 3.4% of the Acinetobacter spp. strains were considered resistant to tigecycline due to their inhibition zone diameters (,13 mm) and MICs determined by broth microdilution (.2 mg/L). 1 The service microbiology laboratory of our hospital has reported tigecycline disc diffusion susceptibility results for Acinetobacter spp. based on the interpretative breakpoints proposed by Jones et al.,
2 which indicated that most clinical isolates of Acinetobacter spp. were not susceptible to tigecycline. There were several observations on the effect of the susceptibility test media on the MICs of tigecycline. Hope et al. 3 found that the MIC of tigecycline was raised in aged media. Fernandez-Mazarasa et al. Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org discrepancy in tigecycline susceptibility for Acinetobacter spp. might be due to a difference in the type of MHA.
We performed tigecycline disc diffusion susceptibility for 102 strains of Acinetobacter spp. isolated from different patients. These isolates were resistant to all b-lactams, aminoglycosides and fluoroquinolones. In vitro susceptibility of Acinetobacter spp. to tigecycline was determined by the Kirby -Bauer disc diffusion method using a paper disc containing 15 mg of tigecycline per disc (BD, USA). The MHAs were purchased from BD (Thailand) and Oxoid Company (Thailand), and they were freshly prepared. The methodology for susceptibility testing was performed by direct colony suspension according to the guidelines suggested by the CLSI. 5 Quality control was performed by testing the susceptibility of Escherichia coli ATCC 25922. The susceptibility tests using both types of MHAs were performed concurrently under identical conditions. The comparison of tigecycline inhibition zone diameters on MHA (BD) and MHA (Oxoid) for 102 isolates of Acinetobacter spp. is shown in Figure 1 . The inhibition zone diameters observed on MHA (Oxoid) were consistently smaller than those on MHA (BD), with a mean difference of 3.5 mm and a range from 1 to 6 mm. The inhibition zone diameters on MHA (Oxoid) and MHA (BD) were significantly correlated (r ¼ 0.95, P , 0.001). The distribution of tigecycline disc diffusion susceptibility for Acinetobacter spp. performed on MHA (BD) and MHA (Oxoid) is shown in Table 1 . The susceptibility of Acinetobacter spp. to tigecycline using MHA (BD) was 86.2%, whereas that using MHA (Oxoid) was only 28.5%. We also measured the content of manganese in both types of MHAs by atomic absorption and found that the content of manganese in MHA (Oxoid) was three times more than that in MHA (BD). Therefore, the discrepancy in inhibition zone diameters between MHA (Oxoid) and MHA (BD) might be due to a difference in the manganese content in MHAs. However, there could be other associated factors for such a discrepancy, and more studies are required. The aforementioned observations warrant a clinical study to determine the efficacy of tigecycline for therapy of Acinetobacter spp. infections in order to consider which type of MHA is more appropriate for tigecycline disc diffusion susceptibility for Acinetobacter spp. Meanwhile, the results of tigecycline disc diffusion susceptibility for Acinetobacter spp. in MHA (Oxoid) should be cautiously reported and interpreted.
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